Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013

[1]  C. Bombardier,et al.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.

[2]  Changgui Li,et al.  Metabolic syndrome, diabetes, and hyperuricemia , 2013, Current opinion in rheumatology.

[3]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[4]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[5]  M. Eren,et al.  Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. , 2012, The American journal of cardiology.

[6]  Shuai Leng,et al.  Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. , 2011, Radiology.

[7]  M. González-Gay,et al.  An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting: The Gout Evaluation and Management Study , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[9]  P. Lipsky,et al.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.

[10]  J. Singh,et al.  Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities , 2011, The Journal of Rheumatology.

[11]  A. So,et al.  Extended Report , 2022 .

[12]  D. Khanna,et al.  Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. , 2011, Rheumatology.

[13]  Y. Chiu,et al.  Role of Ultrasonography in Diagnosing Gouty Arthritis , 2011 .

[14]  M. Barclay,et al.  Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. , 2011, Arthritis and rheumatism.

[15]  Sung Woo Kim,et al.  Serum uric acid levels and the risk of type 2 diabetes: a prospective study. , 2010, The American journal of medicine.

[16]  J. Wolf,et al.  Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche , 2010 .

[17]  I. Reid,et al.  Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial , 2010, Annals of the rheumatic diseases.

[18]  H. Schumacher,et al.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.

[19]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[20]  C. van Weel,et al.  Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care , 2009, Annals of the rheumatic diseases.

[21]  H. Schumacher,et al.  Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout , 2009, The Journal of Rheumatology.

[22]  C. McCulloch,et al.  Risk factors for end-stage renal disease: 25-year follow-up. , 2009, Archives of internal medicine.

[23]  H. Schumacher,et al.  Clinical Diagnostic Criteria for Gout: Comparsion With the Gold Standard of Synovial Fluid Crystal Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[24]  Duk-Hee Kang,et al.  Uric acid and cardiovascular risk. , 2008, The New England journal of medicine.

[25]  W. Taylor,et al.  The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. , 2008, Clinical and experimental rheumatology.

[26]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[27]  Hyon K. Choi,et al.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study , 2008, BMJ : British Medical Journal.

[28]  V. Strand,et al.  Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans , 2007, Annals of the rheumatic diseases.

[29]  K. Pfeiffer,et al.  The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  F. Perez-Ruiz,et al.  Ultrasonographic measurement of tophi as an outcome measure for chronic gout. , 2007, The Journal of rheumatology.

[31]  F. Turgut,et al.  Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions , 2007, International Urology and Nephrology.

[32]  A. Hingorani,et al.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.

[33]  R. Willburger,et al.  Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.

[34]  R. Cianci,et al.  Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. , 2007, European review for medical and pharmacological sciences.

[35]  J. Nolla,et al.  Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. , 2006, Arthritis and rheumatism.

[36]  A. Folsom,et al.  Serum uric acid and risk of ischemic stroke: the ARIC Study. , 2006, Atherosclerosis.

[37]  A. Hofman,et al.  Uric Acid Is a Risk Factor for Myocardial Infarction and Stroke: The Rotterdam Study , 2006, Stroke.

[38]  Payam Kabiri,et al.  DIFFERENT DURATION OF COLCHICINE FOR PREVENTING RECURRENCE OF GOUTY ARTHRITIS , 2006 .

[39]  P Netter,et al.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[40]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[41]  M. Abel,et al.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.

[42]  Naoyuki Kamatani,et al.  A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. , 2004, Arthritis and rheumatism.

[43]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[44]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[45]  R. Glynn,et al.  Asymptomatic Hyperuricemia. Risks and Consequences in the Normative Aging Study , 1987 .

[46]  Robert G. Godfrey,et al.  Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.

[47]  Y. Solak,et al.  Asymptomatic Hyperuricemic Subjects with Normal Renal Function , 2011 .

[48]  L. See,et al.  Gout: an independent risk factor for all-cause and cardiovascular mortality. , 2010, Rheumatology.

[49]  K. Leung,et al.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  T. Hada,et al.  Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients , 1991 .